Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer.

@article{George2017GenomicAO,
  title={Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer.},
  author={Julie George and Motonobu Saito and Koji Tsuta and Reika Iwakawa and Kouya Shiraishi and Andreas H Scheel and Shinsuke Uchida and Shun-ichi j. Watanabe and Ryo Nishikawa and Masayuki Noguchi and Martin Peifer and Se Jin Jang and Iver Petersen and Reinhard Buettner and Curtis C. Harris and Jun Yokota and Roman K. Thomas and Takashi Kohno},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 5},
  pages={
          1220-1226
        }
}
Purpose: Programmed death ligand-1 (PD-L1), encoded by the CD274 gene, is a target for immune checkpoint blockade; however, little is known about genomic CD274 alterations. A subset of small-cell lung cancer (SCLC) exhibits increased copy number of chromosome 9p24, on which CD274 resides; however, most SCLCs show low expression of PD-L1. We therefore examined whether CD274 is a target of recurrent genomic alterations.Experimental Design: We examined somatic copy number alterations in two… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.

  • Japanese journal of clinical oncology
  • 2018
VIEW 9 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  • The New England journal of medicine
  • 2015
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Pembrolizumab for the treatment of non-small cell lung cancer.

  • Expert opinion on biological therapy
  • 2016
VIEW 1 EXCERPT